Efficacy and Safety of Prophylactic Vaccines against Cervical HPV Infection and Diseases among Women: A Systematic Review & Meta-Analysis

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

(2010) Sven-Eric Olsson et al.   Human vaccines & immunotherapeutics

The Health Technology Assessment of bivalent HPV vaccine Cervarix® in Italy

(2010) Giuseppe La Torre et al.   VACCINE

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 Years

(2009) Cosette M. Wheeler et al.   JOURNAL OF INFECTIOUS DISEASES

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

(2009) Darron R. Brown et al.   JOURNAL OF INFECTIOUS DISEASES

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial

(2009) Nubia Muñoz et al.   LANCET

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

(2009) J Paavonen et al.   LANCET

Pregnancy and Infant Outcomes in the Clinical Trials of a Human Papillomavirus Type 6/11/16/18 Vaccine

(2009) Suzanne M. Garland et al.   OBSTETRICS AND GYNECOLOGY

Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine

(2009) Ali Rowhani-Rahbar et al.   VACCINE